X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (55) 55
humans (52) 52
chemistry (38) 38
human necessities (38) 38
hygiene (38) 38
medical or veterinary science (38) 38
metallurgy (38) 38
preparations for medical, dental, or toilet purposes (38) 38
organic chemistry (32) 32
animals (25) 25
oncology (25) 25
heterocyclic compounds (24) 24
cell line, tumor (22) 22
biochemistry & molecular biology (18) 18
mice (18) 18
protein kinase inhibitors - pharmacology (18) 18
acyclic, carbocyclic or heterocyclic compounds containingelements other than carbon, hydrogen, halogen, oxygen, nitrogen,sulfur, selenium or tellurium (17) 17
antineoplastic agents - pharmacology (17) 17
biochemistry (17) 17
cancer (16) 16
beer (14) 14
compositions or test papers therefor (14) 14
compositions thereof (14) 14
condition-responsive control in microbiological orenzymological processes (14) 14
culture media (14) 14
enzymology (14) 14
investigating or analysing materials by determining theirchemical or physical properties (14) 14
measuring (14) 14
measuring or testing processes involving enzymes, nucleicacids or microorganisms (14) 14
microbiology (14) 14
microorganisms or enzymes (14) 14
mutation or genetic engineering (14) 14
physics (14) 14
processes of preparing such compositions (14) 14
propagating, preserving or maintaining microorganisms (14) 14
spirits (14) 14
testing (14) 14
tyrosine kinase (14) 14
vinegar (14) 14
wine (14) 14
expression (12) 12
mutations (12) 12
anaplastic lymphoma kinase (11) 11
apoptosis (11) 11
cell biology (11) 11
hemic and lymphatic diseases (11) 11
mutation (11) 11
specific therapeutic activity of chemical compounds ormedicinal preparations (11) 11
gene (10) 10
peptides (10) 10
proteins (10) 10
receptor protein-tyrosine kinases - antagonists & inhibitors (10) 10
alk (9) 9
activation (8) 8
apoptosis - drug effects (8) 8
crizotinib (8) 8
female (8) 8
hematology (8) 8
inhibitors (8) 8
molecular sequence data (8) 8
protein (8) 8
protein kinase inhibitors - chemistry (8) 8
signal transduction (8) 8
chemistry, medicinal (7) 7
growth (7) 7
imatinib mesylate (7) 7
kinases (7) 7
protein-tyrosine kinases - metabolism (7) 7
proto-oncogene proteins c-ret - antagonists & inhibitors (7) 7
pyrimidines - pharmacology (7) 7
tumors (7) 7
tyrosine (7) 7
acquired-resistance (6) 6
antineoplastic agents - therapeutic use (6) 6
cell line (6) 6
cell lung-cancer (6) 6
drug resistance (6) 6
drug resistance, neoplasm - genetics (6) 6
fusion (6) 6
gene expression regulation, neoplastic (6) 6
identification (6) 6
inhibition (6) 6
lung cancer (6) 6
lymphomas (6) 6
male (6) 6
models, molecular (6) 6
piperazines - pharmacology (6) 6
protein-tyrosine kinases - antagonists & inhibitors (6) 6
protein-tyrosine kinases - genetics (6) 6
receptor tyrosine kinase (6) 6
research (6) 6
resistance (6) 6
ret (6) 6
transcription (6) 6
tumor cells, cultured (6) 6
amino acid sequence (5) 5
base sequence (5) 5
bcl-2 (5) 5
benzamides (5) 5
binding sites (5) 5
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (128) 128
French (21) 21
German (11) 11
Chinese (1) 1
Danish (1) 1
Italian (1) 1
Polish (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 11/2018, Volume 104, pp. 231 - 232
Journal Article
Oncogene, ISSN 0950-9232, 06/2018, Volume 37, Issue 24, pp. 3301 - 3316
Nuclear activated beta-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target. Using human CRC cells harboring... 
PROTEIN | EXCHANGER REGULATORY FACTOR | PDZ DOMAIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | COLON | CELL BIOLOGY | NUCLEAR NHERF1 | FACTOR-1 | ONCOLOGY | PATHWAY | GROWTH | GENETICS & HEREDITY | BINDING | SMALL-MOLECULE INHIBITION | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Gene Expression Regulation, Neoplastic | Cell Survival - genetics | Apoptosis - genetics | Phosphoproteins - antagonists & inhibitors | Protein Transport - drug effects | Phosphoproteins - metabolism | Phosphoproteins - chemistry | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Gene Knockdown Techniques | Sodium-Hydrogen Exchangers - metabolism | Transcription Factor 4 - metabolism | Colorectal Neoplasms - drug therapy | Sodium-Hydrogen Exchangers - genetics | Sodium-Hydrogen Exchangers - antagonists & inhibitors | Cell Survival - drug effects | Transcription Factor 4 - genetics | Phosphoproteins - genetics | Sulfonamides - pharmacology | beta Catenin - genetics | Sodium-Hydrogen Exchangers - chemistry | beta Catenin - antagonists & inhibitors | Cell Line, Tumor | Mutation | Colorectal Neoplasms - pathology | Chromatin | Immunoprecipitation | Cell survival | Wnt protein | Na+/H+-exchanging ATPase | Therapeutic applications | Colorectal carcinoma | Colorectal cancer | Extracellular signal-regulated kinase | Caspase | Poly(ADP-ribose) polymerase | Ribonucleic acid--RNA | Caspase-3 | Autophagy | Carcinogenesis | K-Ras protein | Adenomatous polyposis coli | β-catenin | Hepatocyte nuclear factor 1 | Phagocytosis | Apoptosis | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 2, pp. djt378 - djt378
Journal Article
World Journal of Clinical Oncology, ISSN 2218-4333, 10/2015, Volume 6, Issue 5, pp. 104 - 108
Aberrant forms of the anaplastic lymphoma kinase (ALK) are involved in the pathogenesis of several types of cancer, including anaplastic large cell lymphoma,... 
Crizotinib | Drug combinations | Drug resistance | Protein kinase inhibitors | Anaplastic lymphoma kinase tyrosine kinase receptor
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 2, pp. 84 - 85
Journal Article
Neoplasia, ISSN 1476-5586, 05/2018, Volume 20, Issue 5, pp. 467 - 477
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2015, Volume 4, Issue 1, pp. 5 - 7
The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in the onset of several malignancies. In particular, ALK is the driving oncogenic... 
Clinical trial | Non-small cell lung cancer (NSCLC) | Anaplastic lymphoma kinase (ALK) | Targeted molecular therapy | clinical trial | targeted molecular therapy | anaplastic lymphoma kinase (ALK)
Journal Article
Cancers, ISSN 2072-6694, 12/2018, Volume 10, Issue 12, p. 509
Targeted therapy is an effective, rational, and safe approach to solid and hematological tumors treatment. Unfortunately, a significant fraction of patients... 
Inhibitors | Personalized medicine | Targeted therapy | Oncogene | Cancer | ALK | inhibitors | targeted therapy | ACQUIRED-RESISTANCE | SENSITIVITY | FOLLOW-UP | MECHANISMS | oncogene | personalized medicine | CHRONIC MYELOID-LEUKEMIA | CELL LUNG-CANCER | ONCOLOGY | DRUG-ADDICTION | CRIZOTINIB | cancer
Journal Article
Nature Genetics, ISSN 1061-4036, 01/2013, Volume 45, Issue 1, pp. 18 - 24
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e51449 - e51449
Activation of Wnt signalling due to inability to degrade beta-catenin is found in >85% of colorectal cancers. Approximately half of colon cancers express a... 
COLON-CANCER | CARCINOMA-CELLS | IN-VITRO | K-RAS | THYROID CARCINOMAS | MULTIDISCIPLINARY SCIENCES | PYRVINIUM PAMOATE | PANCREATIC TUMOR-GROWTH | BETA-CATENIN | FARNESYLTHIOSALICYLIC ACID | PROMOTES APOPTOSIS | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Farnesol - pharmacology | Humans | ras Proteins - metabolism | Wnt Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Salicylates - chemistry | Salicylates - pharmacology | Colorectal Neoplasms - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Colorectal Neoplasms - metabolism | Farnesol - chemistry | Perylene - analogs & derivatives | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Perylene - chemistry | Pyrvinium Compounds - chemistry | ras Proteins - antagonists & inhibitors | Perylene - pharmacology | Drug Synergism | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Farnesol - analogs & derivatives | Mice | Wnt Proteins - antagonists & inhibitors | Pyrvinium Compounds - pharmacology | Prevention | Gene mutations | Cell death | Analysis | Genes | Cancer cells | Colorectal cancer | Health aspects | Cancer | Health sciences | Biotechnology | Wnt protein | Transcription | Gene regulation | Colorectal carcinoma | Genomes | Myc protein | Kinases | Cancer therapies | Synergism | K-Ras protein | Proteins | Synergistic effects | β-catenin | Cell growth | Colon cancer | CD44 antigen | Colon | Inhibition | RNA-mediated interference | Abnormalities | Cyclin-dependent kinases | Survivin | Gene expression | Signaling | Inhibitors | Mutation | Apoptosis | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 12/2018, Volume 78, Issue 24, pp. 6866 - 6880
Targeted therapy changed the standard of care in ALK-dependent tumors. However, resistance remains a major challenge. Lorlatinib is a third-generation ALK... 
ACTIVATION | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | PATHWAY | TYROSINE KINASE | ACQUIRED-RESISTANCE | LUNG ADENOCARCINOMA | CRIZOTINIB | SENSITIVITY | TUMOR-CELLS | ALK/ROS1 INHIBITOR
Journal Article
Journal Article
ChemMedChem, ISSN 1860-7179, 08/2017, Volume 12, Issue 16, pp. 1390 - 1398
Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary... 
kinases | pyridines | pyrimidines | hit-to-lead | RET inhibitors | Urea | Pyrimidines | Pyridine | Lung cancer, Non-small cell | Thyroid diseases | Thyroid cancer | Inhibitors | Multiple endocrine neoplasia | Lung cancer | Lung carcinoma | Kinases | Papillary thyroid carcinoma | Mutants | Thyroid | Cancer | Thyroid carcinoma
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2012, Volume 87, Issue 11, pp. E125 - E128
BCR/ABL (Breakpoint Cluster Region protein/Abelson tyrosine-protein kinase 1) kinase domain (KD) mutations represent the most frequently described mechanism of... 
CELLS | IN-VITRO | IMATINIB | ALPHA-1-ACID GLYCOPROTEIN | RESISTANCE | MECHANISMS | MUTATIONS | HEMATOLOGY | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | T315I MUTANT | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Sequence Analysis, Protein | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Transfection | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Protein-Tyrosine Kinases - chemistry | Antineoplastic Agents - pharmacology | Cell Culture Techniques | Tumor Cells, Cultured | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Mutagenesis, Site-Directed | Antineoplastic Agents - chemistry | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 902 - 902
Journal Article